Biotek-snakken — Juni 2021
-
Veloxis gav mig 6 x investeringen. Nu prøver jeg først og fremmest lykken hos AGTC, som udvikler en gen-be
handling imod blindhed med en rigtig god sikkerhedsprofil. Ligeledes har de en meget lovende kur imod høretab (samarbejdspartner) dog i tidlig fase. Kursmål ligger imellem $8 og $35 og pt er kurs er $4,1 -
Lyder også spændende.Vi gik med i søgsmål ud fra 100/5= 20 gange pengene retur
-
Zymeworks: Ved ikke om det er blevet postet før, men XB002 rekrutterer: https://clinicaltrials.gov/ct2/show/NCT04925284?term=exelixis&draw=2&rank=10
-
Har danske biotekselskaber scoret selvmål?
https://www.proinvestor.com/index.php?p=debat_1&postid=94610 -
""Jeg er ikke i tvivl om, at medicinal- og farmaaktierne vil komme igen. Der er udsigt til, at væksten topper i Europa i løbet af tredje kvartal, og så bliver det tid til at skifte over mod den type aktier igen, hvor man er mere sikker på den underliggende pengestrøm," fortsætter han."
Strateg tror på comeback til C25-indekset: Medicinal- og farmaaktier vil komme igen
Der kan være comeback til C25-indekset i årets andet halvår efter en svær start på året. Ifølge Investeringsstrateg i Industriens Pension, Christian Blaabjerg, er ikke i tvivl om, at medicinal- og farmaaktierne vil komme igen.
(medwatch.dk)
-
Antibody-drug Conjugates: Coming of Age
In this episode of The Onco’Zine Brief, developed in collaboration with ADC Review | Journal of Antibody-drug Conjugates (at www.ADCReview.com), Peter Hofland, Ph.D. talks with William (Bill) Newell, JD, Chief Executive Officer and a member of the Board of Directors of Sutro Biopharma (www.sutrobio.com) Sutro is a clinical-stage drug discovery, development, and manufacturing company using precise protein engineering and rational design to advance the development of the next-generation oncology therapeutics for unmet medical needs and areas where the current standard of care is suboptimal. To date, Sutro’s technology platform has led to the development of cytokine-based immuno-oncology therapies, antibody-drug conjugates or ADCs, vaccines, and bispecific antibodies. In addition to Sutro’s own pipeline of novel drugs, including STRO-001, a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma, and STRO-002, a folate receptor alpha (FolRα)-targeting ADC, currently being investigated in a Phase 1 clinical trial of patients with ovarian and endometrial cancers, the company is also collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics. Antibody-drug conjugates like STRO-001 and STRO-002, are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker. Today there are 10 approved ADC on the market – and many more in development. And as a result, ADCs have become a powerful class of therapeutic agents in oncology and hematology. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.
Spreaker (www.spreaker.com)
-
Eisai and Bristol Myers Squibb Sign Global Strategic Collaboration to Jointly Develop MORAb-202 » ADC Review
Eisai and Bristol Myers Squibb Sign Global Strategic Collaboration to Jointly Develop MORAb-202 » ADC Review MORAb-202 is Eisai's first ADC.
ADC Review (www.adcreview.com)
-
Daiichi Sankyo Reaffirms Long-term Goals with Increased Investment in ADCs » ADC Review
Daiichi Sankyo Reaffirms Long-term Goals with Increased Investment in ADCs » ADC Review
ADC Review (www.adcreview.com)
-
For at udløse SL - der bliver jo spekuleret voldsomt i aktien.
Mon ikke de får en tilladelse til salg af Sulopenem...safety og effekt ser rigtig fin ud. PDUFA mål er 25. juli, så det er lige om lidt. Gætter på fortsat stigende aktiekurs over sommeren. -
ProInvestor er desværre under massivt hacker angreb lige nu - derfor nede:(
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind